PTOV1

PTOV1 is a cell cycle-regulated adaptor and transcriptional regulator that promotes proliferation by coupling nucleocytoplasmic shuttling to control of growth-related gene expression (PMID:12598323, PMID:30922918). Built from two tandem homologous PTOV domains, it shuttles between the cytoplasm and nucleus in a cell cycle-dependent manner, accumulating in the nucleus at the onset of S phase and forcing entry into S phase with elevated cyclin D1 (PMID:11313889, PMID:12598323). In the nucleus, PTOV1 acts directly on chromatin: an AT-hook-like motif within its PTOV-A domain binds the promoters of ALDH1A1 and CCNG2 to drive their expression, and it associates with mitotic chromosomes (PMID:30922918). Its transcriptional output is bidirectional — it represses Notch target genes HES1 and HEY1 by joining the Notch repressor complex at their promoters until active Notch evicts it (PMID:24684754), antagonizes retinoic acid receptor signaling by competing for CBP together with MED25 and zyxin (PMID:21110951, PMID:23321499), and cooperates with ZNF449 to activate MYC transcription (PMID:40133702). PTOV1 abundance and localization are governed by an SGK2-phosphorylation-dependent switch: phosphorylation at serine 36 enables 14-3-3 binding, which sequesters PTOV1 in the cytosol and shields it from HUWE1-mediated proteasomal degradation, while disruption of this interaction drives nuclear accumulation and turnover; cytosolic 14-3-3-bound PTOV1 induces cJun to drive cell-cycle progression (PMID:34654719). In cancer, PTOV1 drives invasion, stemness and chemoresistance through Notch antagonism, β-catenin/DKK1 signaling, NF-κB and AKT1 activation, and SQSTM1-directed autophagic degradation of p53 (PMID:24684754, PMID:31387622, PMID:33738336, PMID:39229496, PMID:39905441).

1. 2001 Medium

   Established PTOV1 as a novel protein with a distinctive two-domain architecture and defined its baseline subcellular distribution, providing the structural starting point for all later mechanistic work.

   Evidence GFP fusion imaging and immunocytochemistry in cultured cells

   PMID:11313889

   Open questions at the time

   • No function assigned to the PTOV domains
   • Perinuclear localization not linked to a molecular activity
2. 2003 Medium

   Showed that PTOV1 localization is cell-cycle gated and functionally drives proliferation, reframing it from a localized protein to an S-phase-coupled growth regulator.

   Evidence Immunofluorescence, GFP live imaging, flow cytometry and cyclin D1 Western blot after serum stimulation

   PMID:12598323

   Open questions at the time

   • Mechanism connecting nuclear entry to S-phase induction unresolved
   • Direct transcriptional targets unidentified
3. 2005 High

   Identified flotillin-1 as a physical partner and positioned PTOV1 as a determinant of partner nuclear import, the first direct interaction underpinning its proliferative role.

   Evidence Reciprocal Co-IP, lipid-raft fractionation, siRNA depletion and proliferation assays

   PMID:15713644

   Open questions at the time

   • Molecular import machinery used by PTOV1 unknown
   • Relationship to its own shuttling not defined
4. 2006 Medium

   Placed PTOV1 downstream of androgen receptor signaling, linking its expression to a hormonal proliferative stimulus in vascular smooth muscle.

   Evidence Microarray, qRT-PCR and siRNA knockdown with proliferation readout in AR-positive VSMCs

   PMID:16639697

   Open questions at the time

   • Direct AR-responsive elements at the PTOV1 locus not mapped
   • Relevance beyond VSMCs untested
5. 2013 Medium

   Defined PTOV1 as a transcriptional antagonist of retinoic acid signaling by competing for the coactivator CBP, the first specific transcriptional mechanism for the protein.

   Evidence Co-IP, ChIP, reporter assays and nuclear translocation imaging implicating MED25 and zyxin in CBP competition

   PMID:21110951 PMID:23321499

   Open questions at the time

   • Whether PTOV1 contacts CBP directly or via partners unresolved
   • Genome-wide RAR targets affected not defined
6. 2014 High

   Established PTOV1 as a sequence-context chromatin-associated repressor of Notch targets and a driver of invasion and metastasis, demonstrating bidirectional transcriptional control with in vivo consequence.

   Evidence ChIP, Co-IP, reporter assays, Drosophila genetic epistasis and SCID-Beige xenografts

   PMID:24684754

   Open questions at the time

   • How PTOV1 is recruited to Notch repressor complexes not defined
   • Whether DNA binding underlies promoter association unknown at this stage
7. 2019 High

   Provided direct biochemical evidence that PTOV1 is a DNA-binding protein through an AT-hook-like motif in its PTOV-A domain, converting prior promoter-association data into an intrinsic activity.

   Evidence EMSA, ChIP and motif mutagenesis at ALDH1A1/CCNG2 promoters plus mitotic chromosome IHC

   PMID:30922918

   Open questions at the time

   • Genome-wide DNA-binding landscape unmapped
   • Sequence specificity of the AT-hook motif not fully defined
8. 2019 Medium

   Extended PTOV1's proliferative network through PIN1 interaction and downstream control of cyclin D1, c-Myc and β-catenin with apoptotic consequences upon depletion.

   Evidence Co-IP, siRNA knockdown, Western blot and flow cytometry in breast cancer cells

   PMID:31083670

   Open questions at the time

   • Whether PIN1 isomerizes PTOV1 directly untested
   • Mechanism linking PTOV1 to the listed effectors indirect
9. 2021 High

   Resolved how PTOV1 stability and localization are controlled, defining an SGK2-Ser36-phosphorylation/14-3-3/HUWE1 axis that gates cytosolic sequestration versus nuclear accumulation and degradation.

   Evidence Phospho-mutagenesis, Co-IP, proteasome-inhibitor rescue and subcellular fractionation

   PMID:34654719

   Open questions at the time

   • Signals upstream of SGK2 activation toward PTOV1 unknown
   • Whether nuclear PTOV1 is the active transcriptional pool not directly shown here
10. 2021 Medium

    Linked PTOV1 to NF-κB activation as a mechanism of chemoresistance, broadening its pro-survival signaling reach.

    Evidence Overexpression/knockdown, phospho-IKK and nuclear p65 Western blots, NF-κB inhibitor rescue and xenografts in ovarian cancer

    PMID:33738336

    Open questions at the time

    • Direct molecular step connecting PTOV1 to IKK unknown
    • Whether effect is transcriptional or post-translational unresolved
11. 2024 Medium

    Connected PTOV1 to AKT1 pathway activation and cell-cycle inhibitor suppression in colorectal cancer, adding a kinase-signaling arm to its proliferative function.

    Evidence Knockdown/overexpression, p-AKT1/P21/P27 Western blots and MK2206 rescue with proliferation assays

    PMID:39229496

    Open questions at the time

    • Mechanism of AKT1 activation by PTOV1 not defined
    • Direct versus indirect coupling untested
12. 2025 Medium

    Revealed a post-translational route by which PTOV1 destabilizes p53 — recruitment to SQSTM1 for autophagic degradation — and a ZNF449 partnership driving MYC, deepening its pro-tumor mechanism and identifying a druggable interaction interface.

    Evidence IP-MS, Co-IP, GST pull-down, TEM autophagy imaging, rescue with p53 overexpression/SQSTM1 knockdown, reporter assays and TAT-peptide disruption xenografts

    PMID:39905441 PMID:40133702

    Open questions at the time

    • How PTOV1 triggers autophagy initiation unresolved
    • Whether ZNF449/MYC activation requires PTOV1 DNA binding untested

• How PTOV1's intrinsic AT-hook DNA binding, its many partner interactions, and its NF-κB/AKT1 signaling outputs are integrated into a single coherent regulatory program remains undefined.
• No structure of the PTOV domains or DNA-bound complex
• Genome-wide direct target set unmapped
• Whether signaling effects are downstream of its transcriptional activity or independent is unresolved